CAT-2054 + atorvastatin

CAT-2054 + atorvastatin is an **investigational oral combination therapy** being evaluated for the treatment of hypercholesterolemia. CAT-2054 is a small molecule that targets and modulates the **Sterol Regulatory Element-Binding Protein (SREBP) pathway**, a master regulator of lipid metabolism that impacts LDL cholesterol, triglycerides, glucose metabolism, and potentially liver fat. Atorvastatin is a widely used statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis. Early clinical studies by Catabasis Pharmaceuticals demonstrate that CAT-2054 is well-tolerated both as monotherapy and when combined with atorvastatin, showing additive potential for lowering LDL-C and no significant effect on atorvastatin pharmacokinetics. The primary indication under development is for patients with hypercholesterolemia who have insufficient response to existing therapies. Combination therapy aims to provide a novel mechanism of action on top of standard high-intensity statin treatment, targeting multiple aspects of cholesterol metabolism via SREBP modulation (affecting proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase, and NPC1L1)[1][3][4][5].